The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines

Jacob J. Elmer, Matthew D. Christensen, Sutapa Barua, Jennifer Lehrman, Karmella Haynes, Kaushal Rege

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eukaryotic cells maintain an immense amount of genetic information by tightly wrapping their DNA around positively charged histones. While this strategy allows human cells to maintain more than 25,000 genes, histone binding can also block gene expression. Consequently, cells express histone acetyl transferases (HATs) to acetylate histone lysines and release DNA for transcription. Conversely, histone deacetylases (HDACs) are employed for restoring the positive charge on the histones, thereby silencing gene expression by increasing histone-DNA binding. It has previously been shown that histones bind and silence viral DNA, while hyperacetylation of histones via HDAC inhibition restores viral gene expression. In this study, we demonstrate that treatment with Entinostat, an HDAC inhibitor, enhances transgene (luciferase) expression by up to 25-fold in human prostate and murine bladder cancer cell lines when used with cationic polymers for plasmid DNA delivery. Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations. While this moderate G0/G1 arrest disappeared at higher concentrations, a modest increase in the fraction of apoptotic cells and a decrease in cell proliferation were observed, consistent with the known anticancer effects of the drug. DNase accessibility studies revealed no significant change in plasmid transcriptional availability with Entinostat treatment. However, quantitative PCR studies indicated that Entinostat treatment, at the optimal dose for enhancing transgene expression, led to an increase in the amount of plasmid present in the nucleus in two cancer cell lines. Taken together, our results show that Entinostat enhances polymer- mediated transgene expression and can be useful in applications related to transient protein expression in mammalian cells.

Original languageEnglish (US)
JournalBiotechnology and Bioengineering
DOIs
StateAccepted/In press - 2015

Fingerprint

Histone Deacetylase Inhibitors
Transgenes
Histones
Polymers
Cells
DNA
Cell Line
Gene expression
Histone Deacetylases
Neoplasms
Plasmids
Gene Expression
Cell proliferation
Transcription
Cell Cycle Resting Phase
Viral Genes
Deoxyribonucleases
entinostat
Viral DNA
G1 Phase

Keywords

  • Acetylation
  • Epigenetic silencing
  • Histones
  • Non-viral gene delivery
  • Transient protein expression

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines. / Elmer, Jacob J.; Christensen, Matthew D.; Barua, Sutapa; Lehrman, Jennifer; Haynes, Karmella; Rege, Kaushal.

In: Biotechnology and Bioengineering, 2015.

Research output: Contribution to journalArticle

Elmer, Jacob J. ; Christensen, Matthew D. ; Barua, Sutapa ; Lehrman, Jennifer ; Haynes, Karmella ; Rege, Kaushal. / The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines. In: Biotechnology and Bioengineering. 2015.
@article{1857de0526074db2aac8eb5b26a183c1,
title = "The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines",
abstract = "Eukaryotic cells maintain an immense amount of genetic information by tightly wrapping their DNA around positively charged histones. While this strategy allows human cells to maintain more than 25,000 genes, histone binding can also block gene expression. Consequently, cells express histone acetyl transferases (HATs) to acetylate histone lysines and release DNA for transcription. Conversely, histone deacetylases (HDACs) are employed for restoring the positive charge on the histones, thereby silencing gene expression by increasing histone-DNA binding. It has previously been shown that histones bind and silence viral DNA, while hyperacetylation of histones via HDAC inhibition restores viral gene expression. In this study, we demonstrate that treatment with Entinostat, an HDAC inhibitor, enhances transgene (luciferase) expression by up to 25-fold in human prostate and murine bladder cancer cell lines when used with cationic polymers for plasmid DNA delivery. Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations. While this moderate G0/G1 arrest disappeared at higher concentrations, a modest increase in the fraction of apoptotic cells and a decrease in cell proliferation were observed, consistent with the known anticancer effects of the drug. DNase accessibility studies revealed no significant change in plasmid transcriptional availability with Entinostat treatment. However, quantitative PCR studies indicated that Entinostat treatment, at the optimal dose for enhancing transgene expression, led to an increase in the amount of plasmid present in the nucleus in two cancer cell lines. Taken together, our results show that Entinostat enhances polymer- mediated transgene expression and can be useful in applications related to transient protein expression in mammalian cells.",
keywords = "Acetylation, Epigenetic silencing, Histones, Non-viral gene delivery, Transient protein expression",
author = "Elmer, {Jacob J.} and Christensen, {Matthew D.} and Sutapa Barua and Jennifer Lehrman and Karmella Haynes and Kaushal Rege",
year = "2015",
doi = "10.1002/bit.25898",
language = "English (US)",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines

AU - Elmer, Jacob J.

AU - Christensen, Matthew D.

AU - Barua, Sutapa

AU - Lehrman, Jennifer

AU - Haynes, Karmella

AU - Rege, Kaushal

PY - 2015

Y1 - 2015

N2 - Eukaryotic cells maintain an immense amount of genetic information by tightly wrapping their DNA around positively charged histones. While this strategy allows human cells to maintain more than 25,000 genes, histone binding can also block gene expression. Consequently, cells express histone acetyl transferases (HATs) to acetylate histone lysines and release DNA for transcription. Conversely, histone deacetylases (HDACs) are employed for restoring the positive charge on the histones, thereby silencing gene expression by increasing histone-DNA binding. It has previously been shown that histones bind and silence viral DNA, while hyperacetylation of histones via HDAC inhibition restores viral gene expression. In this study, we demonstrate that treatment with Entinostat, an HDAC inhibitor, enhances transgene (luciferase) expression by up to 25-fold in human prostate and murine bladder cancer cell lines when used with cationic polymers for plasmid DNA delivery. Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations. While this moderate G0/G1 arrest disappeared at higher concentrations, a modest increase in the fraction of apoptotic cells and a decrease in cell proliferation were observed, consistent with the known anticancer effects of the drug. DNase accessibility studies revealed no significant change in plasmid transcriptional availability with Entinostat treatment. However, quantitative PCR studies indicated that Entinostat treatment, at the optimal dose for enhancing transgene expression, led to an increase in the amount of plasmid present in the nucleus in two cancer cell lines. Taken together, our results show that Entinostat enhances polymer- mediated transgene expression and can be useful in applications related to transient protein expression in mammalian cells.

AB - Eukaryotic cells maintain an immense amount of genetic information by tightly wrapping their DNA around positively charged histones. While this strategy allows human cells to maintain more than 25,000 genes, histone binding can also block gene expression. Consequently, cells express histone acetyl transferases (HATs) to acetylate histone lysines and release DNA for transcription. Conversely, histone deacetylases (HDACs) are employed for restoring the positive charge on the histones, thereby silencing gene expression by increasing histone-DNA binding. It has previously been shown that histones bind and silence viral DNA, while hyperacetylation of histones via HDAC inhibition restores viral gene expression. In this study, we demonstrate that treatment with Entinostat, an HDAC inhibitor, enhances transgene (luciferase) expression by up to 25-fold in human prostate and murine bladder cancer cell lines when used with cationic polymers for plasmid DNA delivery. Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations. While this moderate G0/G1 arrest disappeared at higher concentrations, a modest increase in the fraction of apoptotic cells and a decrease in cell proliferation were observed, consistent with the known anticancer effects of the drug. DNase accessibility studies revealed no significant change in plasmid transcriptional availability with Entinostat treatment. However, quantitative PCR studies indicated that Entinostat treatment, at the optimal dose for enhancing transgene expression, led to an increase in the amount of plasmid present in the nucleus in two cancer cell lines. Taken together, our results show that Entinostat enhances polymer- mediated transgene expression and can be useful in applications related to transient protein expression in mammalian cells.

KW - Acetylation

KW - Epigenetic silencing

KW - Histones

KW - Non-viral gene delivery

KW - Transient protein expression

UR - http://www.scopus.com/inward/record.url?scp=84952801910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952801910&partnerID=8YFLogxK

U2 - 10.1002/bit.25898

DO - 10.1002/bit.25898

M3 - Article

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

ER -